United Kingdom multicentre clinical trial of somatrem
| Autor: | P H Rayner, R. D. G. Milner, D I Johnston, N D Barnes, D R Hadden, J M Parkin, David Price, D J Carson, Ieuan A. Hughes, J. M. H. Buckler |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Every Three Months Injections Subcutaneous Growth Growth hormone Injections Intramuscular Antibodies Growth hormone deficiency Internal medicine medicine Humans Child Adverse effect Growth Disorders Clinical Trials as Topic Human Growth Hormone business.industry Somatrem medicine.disease Hormones Surgery Clinical trial Child Preschool Growth Hormone Pediatrics Perinatology and Child Health Female business Intramuscular injection Research Article Hormone medicine.drug |
| Zdroj: | Archives of Disease in Childhood. 62:776-779 |
| ISSN: | 1468-2044 0003-9888 |
| DOI: | 10.1136/adc.62.8.776 |
| Popis: | In a multicentre clinical trial 54 children aged 4.0 to 17.3 years, who had growth hormone deficiency that had not previously been treated, were given biosynthetic methionyl growth hormone (somatrem) 4 units three times a week by subcutaneous or intramuscular injection for one year. Height was measured every three months for at least one year before and during treatment. Forty two patients responded to treatment with an increase in growth of greater than 1.5 cm/year. The remaining 12 who grew more slowly were less obviously short and had a higher pretreatment growth than those who responded. The three who responded and the one who did not had undergone therapeutic spinal irradiation before starting the drug. If a whole year's pretreatment growth rate of less than 5 cm/year had been used as a diagnostic criterion the prediction of those who responded would have slightly improved. About two thirds of the patients developed antibodies against growth hormone and Escherichia coli protein; these were, however, of low and fluctuating titre and binding capacity, and did not influence the response to treatment. No adverse side effects were encountered. We conclude that somatrem is a safe and effective alternative to pituitary growth hormone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|